Mesoridazine

CHEMBL1088 Phase 4 Aprobado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

386.6 g/mol

LogP

4.5

Phase

4

A phenothiazine antipsychotic medication used to treat schizophrenia in patients who have not responded to other treatments. Due to its risk of serious heart rhythm abnormalities, its use is now very limited.

Peso molecular

386,6000 g/mol

LogP

4,50

TPSA

68,10 Å²

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Schizophrenia Bipolar Disorder Obesity

Mecanismo de acción

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

Estructura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CN1CCCCC1CCN1c2ccccc2Sc2ccc([S+](C)[O-])cc21

InChI

InChI=1S/C21H26N2OS2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(26(2)24)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3

Molecular Formula

C21H26N2OS2

HBD / HBA

- / 5

Enlaces Rotables

4

Átomos Pesados

26

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

A phenothiazine antipsychotic medication used to treat schizophrenia in patients who have not responded to other treatments. Due to its risk of serious heart rhythm abnormalities, its use is now very limited.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Mesoridazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1088. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 4078. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

¿Busca información accesible para el paciente?

Mesoridazine en PillFYI

Estructura

Datos Rápidos

Fórmula: C21H26N2OS2

Enlaces externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.